MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Recruiting · NCT06793189 · Registry updated 2026-03-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-03-24 | NCT06793189 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ruijin Hospital | 454 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated First Hospital of China Medical University | Shenyang | China | 1 |
| Peking University Third Hospital | Beijing | China | 71 |
| Shanghai Ruijin Hospital | Shanghai | China | 1 |